Pfizer Seeks FDA Approval for RSV Vaccine for Young Adults, Is Also Conducting RSV Trial for Kids as Young as 2
Pfizer said Tuesday it plans to use data from a clinical trial it concluded last month to seek expanded approval of its RSV vaccine, Abrysvo, for all adults ages 18 and up. The vaccine maker also said it has begun trials for the drug in children ages 2-18. Pfizer plans to use data from a…